| Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| 13F holders | Current |
|---|---|
| Total holders | 37 |
| Opened positions | 5 |
| Closed positions | 4 |
| Increased positions | 8 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 1.55 bn |
| Total shares | 135.01 mm |
| Total puts | 6.30 k |
| Total calls | 46.50 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Hong Seng Technology | 102.44 mm | $159.80 mm |
| Intracoastal Capital | 19.13 mm | $31.57 mm |
| Biotechnology Value Fund L P | 5.95 mm | $11.78 mm |
| Novartis Pharma | 5.00 mm | $12.60 mm |
| Alyeska Investment | 866.50 k | $464.53 mm |
| Envestnet Asset Management | 239.19 k | $128.23 mm |
| MS Morgan Stanley | 197.54 k | $105.90 mm |
| Values First Advisors | 197.52 k | $105.89 mm |
| PVG Asset Management | 157.22 k | $84.28 mm |
| Atria Investments | 133.97 k | $71.82 mm |
